20/02/2010
GeoVax Labs, Inc. reports data on prototype adjuvant – suppplemented HIV vaccine tested in preclinical animal studies
Results from study using non-human primates indicate 70% level of protection from infection; Presentation made at Conference on Retroviruses and Opportunistic Infections.
Read the press release.
GeoVax Labs, Inc.
http://www.geovax.com/
Share this page
DISCLAIMER
The EATG is not responsible for the content of this article. It does not necessarily reflect EATG views or opinions.
FAIR USE NOTICE
The information above may contain copyrighted material which has not always been specifically authorised by the copyright owner. Such material is made available for educational purposes to advance the understanding of scientific, ethical, legal and social issues. It is believed that this constitutes a 'fair use' of any such copyrighted material. This material is distributed without profit via the subscription to the daily digest.
More...
